Deals & Alliances (Pharma & Healthcare)

Deals and Alliances (Pharma & Healthcare) Market Research Reports

Deals and Alliances (Pharma & Healthcare) Market Research Reports, Industry Analysis and Trends

 

Publication Single User License (PDF) Price
Personalized Medicine Partnering Terms and Agreements - Market Research Report

Personalized Medicine Partnering Terms and Agreements

Date Published: Oct 1 2012
The Personalized Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
 
$4,995.00
Medical Devices Contract Research Organizations

Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018

Date Published: Jun 7 2012
Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
 
Summary
 
$3,995.00
Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Date Published: Mar 15 2013

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Summary

$3,900.00
Workforce Reductions in Pharmaceuticals

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward

Date Published: Jun 12 2012
Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward
 
Summary
 
$3,500.00
Biological Strategies in the Emerging Markets Report On BRIC

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

Date Published: Jun 12 2012

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

$3,500.00
Drug Delivery Partnering Terms and Agreements - Market Research Report

Drug Delivery Partnering Terms and Agreements

Date Published: Nov 1 2012
The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
 
$2,995.00
Partnering Deals and Alliances with Big Pharma

Partnering Deals and Alliances with Big Pharma

Date Published: Feb 1 2013
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
 
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:
$2,795.00
Biomarker Partnering Terms & Agreements  - Market Research Report

Biomarker Partnering Terms & Agreements

Date Published: Oct 1 2012
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
 
$2,695.00
Companion Diagnostics Partnering Terms & Agreements - Market Research Report

Companion Diagnostics Partnering Terms & Agreements

Date Published: Oct 1 2012
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
$2,695.00
Bioinformatics Partnering Terms & Agreements  - Market Research Report

Bioinformatics Partnering Terms & Agreements

Date Published: Oct 1 2012
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.
 
• Trends in bioinformatics partnering deals
• Deal terms analysis
• Partnering agreement structure
$2,695.00
Diagnostics Partnering Terms and Agreements - Market Research Report

Diagnostics Partnering Terms and Agreements

Date Published: Oct 1 2012
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
 
$2,695.00
Dermatology Partnering Terms and Agreements  - Market Research Report

Dermatology Partnering Terms and Agreements

Date Published: Oct 1 2012
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors bacterials technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
$2,695.00
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Date Published: Jan 1 2013

Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer’s and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care.

$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Date Published: Jan 2 2013

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long. 2012 saw new drugs approvals for unmet needs, first in class drugs for Anti-obesity, Myelofibrosis, cancers and better drug options for HCV, RA, MS, psoriasis, HCC, dyslipidemia etc.

$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

Date Published: Jan 2 2013

Macro Analysis
• Performance of the Mature Biotech companies recommended by MP Advisors
in 2012 -report card is very impressive and we expect the positive sentiments
to prevail in 2013 and beyond
• Valuation Multiples and Fundamentals- Drivers of Growth.
• MP Advisors’ Proprietary Sum-of-The-Parts Valuation and Top Picks for 2013
• Drug Approvals 2012-15
• Key Milestones During 2013/14
• Impact on revenue 2012-2017 from Patent Expiry and Strategies deployed to
meet the challenges.
• Pipeline of Biosimilar mAbs

$2,500.00
Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Date Published: Jan 14 2014
$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma

Date Published: Jan 3 2013

India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings. Locally acting drugs and targeted drug delivery products make up for the bulk of complex formulation generics.

$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Date Published: Jan 14 2014
$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Date Published: Jan 4 2013

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.

$2,500.00
Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry

Global Pharmaceutical Survey 2012–2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry

Date Published: Mar 9 2012

Synopsis

  • This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. The opinions and forward looking statements of 247 industry executives have been captured in our in-depth survey.
  • The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior marketing decision makers and leading supplier organizations.
$2,000.00

Pages

Shopping cart

0 Items $0.00
Market Research Special Offers
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianB. Braun, Cobham, fiserv, Harris, Wipro, AonMunich Re, Lotte Chemical, National Post, First Data